

ASX ANNOUNCEMENT

Analyst Report and Interactive Roadshow Released

15 May 2009, Sydney, Australia

Medical Therapies Limited (ASX:MTY) has launched the first online Interactive Investor Roadshow eKit™ to inform shareholders and the market in general of the progress of its product development programs.

The roadshow material contains a video interview with Medical Therapies' CEO, Maria Halasz, an independent research report prepared by leading research firm Wise-Owl, the company's latest investor presentation update and a live contact link to the CEO and key business units on the company's website. Investors may access the Interactive Roadshow eKit™ by visiting <http://medicaltherapies0901.interactiveinvestor.com.au>

"We have a very large asset portfolio and it can be difficult for investors to understand the key value drivers of our company," said Medical Therapies' CEO Maria Halasz. "For the first time, a web based interactive roadshow gives control to the investor to get to their preferred level of detail about our business," she added.

This streamlined messaging platform delivers a rich-media environment to a broader range of investors for Medical Therapies. The customised platform of investor information has been developed in collaboration with Wise-Owl and Interactive Investor. The collaboration partners want to facilitate the information flow to retail investors on opportunities that may not otherwise be on their radar.

"When developing the Interactive Roadshow eKit™ package, we wanted to provide a platform suitable for all retail investors to gain access to market insight on small to mid-cap companies they would not otherwise have heard about," said Interactive Investor MD, Susan Werkner.

Investors are encouraged to visit the Interactive Investor Roadshow eKit™ on <http://medicaltherapies0901.interactiveinvestor.com.au>.

end

For further information visit www.medicaltherapies.com.au or contact:

Maria Halasz
CEO
M +61 416 008 413

About Medical Therapies Limited (ASX: MTY):

Medical Therapies Limited is the owner of the largest intellectual property portfolio around midkine globally. Midkine is a native protein expressed during early cancer formation as well as at the onset of inflammatory processes. Therefore it is a promising novel therapeutic and diagnostic target. MTY is committed to the commercialisation of its cancer diagnostic products and novel drug candidates. In addition to its in-house product development program MTY is actively seeking partnership opportunities for its non-core therapeutic and diagnostic assets.

About Interactive Investor

Interactive Investor is Australia's leading specialist in online investor relations communications. Their expertise is based on in-depth IR knowledge, outstanding customer service and first class proprietary technology, in line with ASX best practice standards.

Utilising the latest in technology solutions, the Interactive Investor Roadshow™ platform enables listed companies to reach a wider base of investors locally and worldwide. Clients are provided with a cost-effective, transparent and powerful alternative to print based IR communications thus helping companies transition their investor message to a new, green, online environment. Today, they are a trusted long-term partner to many blue-chip and award winning companies across many industries worldwide.

About Wise-Owl

Wise-owl.com is one of Australia's leading independent investment research firms providing investors with actionable strategies, advice, education and risk management techniques. The Wise-Owl investment philosophy is based on a combination of quantitative, fundamental and technical analysis that has been proven over the years to produce consistent returns.

Investment in biotechnology companies

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Medical Therapies recommends that investors seek professional advice before making an investment in its shares.

